Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation between the expression of PD-L1 and c-Myc. Moreover, the expression of both PD-L1 and c-Myc was associated with poor overall survival. In addition, we confirmed this finding with the PDAC patients in the TCGA database. Using several PDAC cell lines we demonstrated a significant correlation between the expression of PD-L1 and c-Myc. We also found that expression of PD-L1 correlated with high-grade histology. JQ1, an inhibitor of c-Myc inhibited PD-L1 expression and tumor growth. Using xenograft models, we demonstrated that the combination of JQ1 and anti-PD-L1 antibody exerted synergistic inhibition of PDAC growth. Our data demonstrated that the expression of PD-L1 and c-Myc may be helpful prognostic biomarkers, and their inhibition may potentially serve as an effective treatment for PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths worldwide 1 and the fourth leading cause of cancer-related deaths in the Western countries. 2, 3 There are many factors that are associated with the poor survival and treatment challenges of PDAC, including the lack of early detection, high risk of relapse after curative surgery, and poor response to chemotherapy, radiation, molecular targeted therapy, and immunotherapy. 4 While immunotherapy using anti-PD-1/PD-L1 antibodies has been shown to be effective for many types of malignancies, [5] [6] [7] [8] [9] its activity has been limited in PDAC, except in rare cases where the tumors harbor DNA mismatched repair gene deficiencies. 9, 10 Several factors may be related to the poor response of PDAC to immune checkpoint inhibitors. First, PD-L1 expression in tumors is an important indicator of checkpoint immunotherapy efficacy; 11, 12 however, PD-L1 expression in PDAC varies from 16.7% to 90%. [13] [14] [15] [16] Second, the high tumor burden causes immunosuppression in patients with pancreatic cancer. 17 Third, almost all pancreatic cancers have non-immunogenic phenotypes. 17, 18 Among these factors the most important one is likely related to the immunosuppressive microenvironment of PDAC.
Mechanistically, though KRAS is the most commonly mutated oncogene in PDAC. However, c-Myc, a master transcription amplifier, is also commonly overexpressed and aberrantly activated in this disease. 19 Targeting c-Myc for the treatment of PDAC has been an intense focus of the cancer research community. 20 Activation of c-Myc has been shown to stimulate the expression of PD-L1 in some cancer cells causing immune evasion. median tumor diameter was 4 cm. These resections were: 49 (56.3%) pancreaticoduodenectomies, 29 (33.3%) distal pancreatectomies, and 9 (10.4%) total pancreatectomies. The R0 resection rate was 35.6%. No neoadjuvant therapy was used in any patient of this cohort.
Correlation between PD-L1 and c-Myc expression in human PDAC
To understand if the expression of PD-L1 correlates with the level of c-Myc in PDAC, we retrieved the tumor specimens of 87 patients with PDAC and stained them with anti-PD-L1 and anti-c-Myc antibodies. Human placenta and lung tumor tissues were used as positive controls (Figure 1a and b) . We found that PD-L1 was expressed in 31.0% and c-Myc was expressed in 43.7% of the tumors. The expression levels of c-Myc and PD-L1 in PDAC tissues were positively correlated at the protein level (p = 0.001; Table 2 ). We next evaluated the correlation between PD-L1 expression and patient characteristics. We found that compared to PD-L1-negative tumors, the PD-L1-positive tumors were associated with high histological grade (p = 0.007; Table 1 ), but not with sex, age, Because small number of cases in these groups, the survival analysis was meaningless.
PD-L1/c-Myc expression groups (expression of none, either, or both). Using univariate analysis, we found that PD-L1 and c-Myc double-positive tumors were associated with worse OS (HR = 4.0878, p < 0.001; Table 3 ; Figure 2c ) compared to the other groups (PD-L1-positive and c-Mycnegative, PD-L1-negative and c-Myc-positive, and PD-L1 and c-Myc-double negative groups). Multivariate analysis was performed to determine if PD-L1/c-Myc expression remain independent predictors of OS (Table 3) (Table 2) .
Prognostic value of PD-L1/c-Myc expression stratified by tumor TNM stage
To further determine the prognostic value of PD-L1/c-Myc expression, patients were divided into four subgroups based on tumor TNM stage (Table 3) 
c-Myc regulates PD-L1 expression in PDAC
Some recent studies showed that c-Myc regulated PD-L1 expression in certain malignancies. 22, 26, 27 We investigated the expression of PD-L1 and c-Myc in five human PDAC cell lines and one murine PDAC cell line using Western blotting to determine their correlation. c-Myc was expressed at various levels in all six cell lines ( Figure 3a) ; two cell lines showed distinct PD-L1 expression, one showed faint expression, and the others showed no expression (Figure 3a) . The expression of PD-L1 was further confirmed with immunofluorescence ( Figure 3b ) in three human PDAC cell lines (SW1990, BxPC-3, and CFPAC-1). Using shRNA, we found that knockdown of c-Myc significantly reduced PD-L1 expression in SW1990 and BxPC-3 cells (Figure 3c-g ). In addition, overexpression of c-Myc increased the expression of PD-L1 in a dose-dependent manner (Figure 3h-j) .
JQ1 is a BRD4 inhibitor that inhibits c-Myc activity. 28 As shown in Figure 4a -c, JQ1 treatment at 1.6, 3.2, and 4.8 nM decreased the expression of PD-L1 in SW1990 and BxPC-3 cell lines. Based on a xenograft model generated by injecting PDAC cells subcutaneously into athymic nude mice, we also found that inhibition of c-Myc by JQ1 resulted in a significant reduction in PD-L1 protein expression (Figure 4d-g ), indicating that the c-Myc oncogene regulates PD-L1 expression in PDAC cells both in vitro and in vivo. We then retrieved 177 PDAC cases from the TCGA database and investigated the correlation between the level of CD274 (PD-L1) expression and c-Myc. Consistent with our data, CD274 expression was positively correlated with c-Myc expression (Figure 5a ). To better understand the relationship between CD274 and c-Myc, we investigated the correlation between the mRNA expression level of PD-L1 and c-Myc-target genes, 29 We showed that PD-L1 expression correlated well with the expression of several c-Myc target genes including ST3GAL3, BRCA1, SOCS3 and CCNG2 (Figure 5b-e) . We further examined MYCN expression in PDAC and found an inverse correlation between c-Myc and MYCN (Figure 5f ) as well as between CD274 and MYCN (Figure 5g ), suggesting that MYCN may also regulate PD-L1 expression in PDAC. In addition, the majority of the 177 PDAC patients from the TCGA database (96%) had stage I or II disease (Table S1 ). There were no significant differences in the c-Myc and PD-L1 expression between stage I and stage II patients (Figure 6a and b) . The MPC-83 cells express c-Myc and PD-L1 both in vitro and in vivo (Figure 6a and c) . The tumor-bearing mice were treated with JQ1 and an anti-PD -L1 monoclonal antibody (mAb), alone or in combination. As shown in Figure 7a and b, JQ1 and anti-PD-L1 mAb therapy alone resulted in reduced tumor growth compared to that of untreated animals. When the anti-PD-L1 mAb was combined with JQ1, the inhibition of tumor growth was synergistic compared to either anti-PD-L1 or JQ1 therapy alone, as assessed by tumor volume (p = 0.02; p = 0.011) and weight (p = 0.004; 0.008). JQ1 and the anti-PD-L1 mAb also reduced tumor cell proliferation and increased tumor cell apoptosis (Figure 7c and d; Figure S1 ). Moreover, JQ1 amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation (p < 0.001; p < 0.001) while enhanced its induction of tumor cell apoptosis (p < 0.001; p < 0.001). These data suggest that JQ1 and anti-PD-L1 mAb therapy may be an effective combination therapy for PDAC. 
Discussion
Human PDAC is essentially a "cold" tumor and responds poorly to immune checkpoint inhibitors. The expression of PD-L1 may be a factor related to its very poor prognosis and resistance to therapy. 13, 30 We have shown that expression of both c-Myc and PD-L1 was associated with worse outcomes in patients with PDAC compared to either markers alone, indicating that both c-Myc and PD-L1 play are in part responsible for the aggressive biology of PDAC and its poor response to immune checkpoint inhibitors.
Frequently overexpressed in PDAC, c-Myc has been also found to be highly associated with poor patient outcomes. 31, 32 It regulates lactate dehydrogenase A (LDHA), promotes the production of lactate, and contributes to the acidification of the tumor microenvironment which likely limits the efficacy of anti-PD-L1 therapy. [33] [34] [35] We have confirmed that c-Myc regulates the expression of PD-L1 in PDAC as well. And its silencing using shRNA or inhibition via JQ1 suppressed PD-L1 expression in vitro and xenograft models. Our results thus suggest that c-Myc inhibitors might represent potential anti-tumor immunotherapeutic agents for pancreatic cancer. Since c-Myc was shown to directly bind the promoter of PD-L1 to regulate its expression, 22 more studies have explored the relationship between these two proteins in human tumor cells. 26, 28 Our data using our own patient cohort as well as the TCGA database demonstrated that c-Myc expression correlated with PD-L1 expression. We also found that expression of MYCN was correlated with PD-L1 expression based on the TCGA cohort. In addition, c-Myc/PD-L1-double positivity significantly correlated with poor outcomes in PDAC patients. Furthermore, multivariate analyses demonstrated that c-Myc/PD-L1-double positivity was an independent predictor of poor prognosis for this disease. Combination therapy strategies are being actively investigated for overcoming the resistance and turning "non-immunogenic" (cold) neoplasms into "immunogenic" (hot) neoplasms. 17, 35, 36 Several groups have studied various approaches including combining anti-PD-1/PD-L1 therapy with other treatment methods such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, or other immunotherapies. 17 JQ1 is an inhibitor of the epigenetic modifier protein BRD4, 37 which is a transcriptional regulator that controls the expression of c-Myc. 20, 38 JQ1, an inhibitor of c-Myc, has been shown to exert a potent inhibitory effect on PDAC cells.
28 JQ1 is currently being tested in several clinical trials. 39 Our study showed that either JQ1 or anti-PD-L1 mAb alone significantly inhibited tumor growth. However, the combination of both agents resulted in a synergistic effect.
In summary, our data demonstrate that PD-L1 expression correlated with c-Myc expression in PDAC and may serve as prognostic predictors clinically. In addition, the combined inhibition of both molecules may be an effective therapeutic approach for PDAC and worth further investigations.
Materials and methods

Patients and tissue samples
Human pancreatic cancer samples were collected from patients undergoing surgery at Fujian Medical University Union Hospital, Fuzhou, China, from November 2010 to April 2017. All patients received surgery and had histologically confirmed PDAC. Patients with neoadjuvant treatment, inflammatory diseases or active infection were excluded. A total of 87 patients who had been diagnosed with PDAC were enrolled in the study. Data collected and evaluated included sex, age, tumor site, tumor diameter, CA19-9, TNM stage, grade, resection margins, vascular invasion, and postoperative chemotherapy. The stage of each patient was assessed based on the American Joint Committee on Cancer version 7 (AJCC 7). R0 resections were assumed if all tumorfree margins were at least 1 mm wide. Informed consent was obtained before sample collection. transfection was performed using the Lipofectamine 3000 reagent (Invitrogen) and transfection was performed according to the manufacturers' recommendations.
Antibodies and immunoblotting
Anti-PD-L1 (E1L3N, #13684) was obtained from Cell Signaling Technology and the anti-c-Myc antibody (Y69) was from Abcam (ab32072). Western blotting for PD-L1 and c-Myc in pancreatic cancer cells was performed using methods described previously. 40 
Immunohistochemistry (IHC)
Immunohistochemical analysis was performed as previously described. 41 PD-L1 was detected in the cytoplasm and on the cytomembranes of tumor cells, whereas c-Myc was detected in the nucleoplasm of tumor cells. Sections of human placenta and lung cancer tissue were used as positive controls (Figure 1a and  b) . PD-L1 status was defined as positive if ≥40% of tumor cells exhibited cytosolic staining of any intensity. c-Myc status was analyzed based on histopathological scoring, as described by Warner et al., 42 and status was defined as positive based on a score ≥4. All specimens were evaluated by two pathologists who were blinded to the patients' clinical information.
Immunofluorescence
Immunofluorescence assays were performed to identify the location of PD-L1 in pancreatic cancer cells, as previously described. 43 Quantitative PCR (qPCR) c-Myc and PD-L1 mRNA was measured by qPCR using SYBR Premix Ex Taq (Takara, Dalian, China) and normalized to β-actin expression. The qPCR reactions were performed using an ABI Stepone plus Real-Time PCR System (Applied Biosystems). The primer sequences are listed in Supplementary Table 3 .
Flow cytometry analysis
The PD-L1 expression on murine PDAC cells was determined by flow cytometry after staining with anti-mouse specific PD-L1 antibody conjugated with APC (17-5983-42, MIH1, eBioscience).
The cancer genome atlas (TCGA) data analysis
RNAseq and clinical data from 177 patient samples, defined by the TCGA pathologist as PDAC, were obtained from the TCGA Data Portal (https://tcga-data.nci.nih.gov). All data were downloaded from the November 22, 2017 standard dataset. For RNAseq data, expression levels were TPMnormalized and ENSG-ID transformed.
Statistical analysis
Quantitative data were expressed as the mean ± standard deviation (SD) and analyzed based on variance and Student's t-tests. Chi-square tests were performed to compare PD-L1 expression and clinical features. Spearman's rank correlation was evaluated to determine the correlation between PD-L1 and c-Myc expression at the protein level. OS was measured from the date of diagnosis to the day of death from any cause or the last censored follow-up. Survival analysis methods were similar to those previously described. 13 
